ANL - Adlai Nortye Ltd. American Depositary Shares

ANL - Adlai Nortye Ltd. American Depositary Shares

https://www.adlainortye.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025 - Adlai Nortye ( NASDAQ:ANL )

Benzinga • 5 months ago • score: 0.12

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd.

Adlai Nortye Ltd. Sponsored ADR ( ANL ) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Commentary • 1 year ago • score: 0.16

Adlai Nortye Ltd. Sponsored ADR (ANL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the ...

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy ( dCRT ) at ASCO 2024

GlobeNewswire • 1 year, 3 months ago • score: 0.09

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...

Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR ( ANL ) This Year?

Zacks Commentary • 1 year, 4 months ago • score: 0.35

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Is Adlai Nortye Ltd. Sponsored ADR ( ANL ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 1 year, 4 months ago • score: 0.43

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Elevance Health (ELV) have performed compared to their sector so far this year.

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

GlobeNewswire • 1 year, 5 months ago • score: 0.08

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.

52W High

$3.89

52W Low

$1.10

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2024-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

3.81

P/S (TTM) (<3 favorable)

33.29

P/B (<3 favorable)

2.53

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

14.25%

Institutions (25–75% balanced)

0.19%

Shares Outstanding

31,236,900

Float

59,847,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-06-30 (Overview)

Revenue (TTM)

1,940,000

Gross Profit (TTM)

1,940,000

EPS (TTM)

-1.62

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-12.21%

ROE (TTM) (>15% strong)

-1.03%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.18

Momentum

Bearish momentum

Value

0.0554

Previous

0.0547

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025